You are here: Industry Insights > Market News > Drug for children with spinal muscular atrophy too expensive, HSE says

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

water filter

WATER FILTER FOR WATER PURIFIER

DUST BAG

Small dust filter

HUMIDIFIER FILTER

Oil fume adsorption filter

Drug for children with spinal muscular atrophy too expensive, HSE says

firstwordpharmaFebruary 23, 2019

Tag: HSE , Spinal Muscular Atrophy , Children

Favorites

The Health Service Executive has determined that the spinal muscle atrophy drug Spinraza is not cost-effective at its current price, The Irish Times reported Friday.
The HSE determined that the treatment could carry a cost of 20 million euros over five years, while it was not able to reach an accord with the manufacturer regarding a viable price.
The regulator noted that Spinraza would carry a cost of 600 000 euros for the first year and 380 000 euros for each successive year.
The HSE stated that it was "obligated to ensure that expenditure of this scale must represent evidence of clinical and cost-effectiveness."
Register as Visitor to CPhI China 2019!

Previous:Delhi HC sets aside govt ban on Lupin's anti-diabetic drug Gluconorm-30

Next:Orchard Therapeutics Presents Two-Year Follow-Up Data Versus Historical Control from Registrational Trial of OTL-101 for the Treatment of ADA-SCID

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Drug for children with spinal muscular atrophy too expensive, HSE says | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

Drug for children with spinal muscular atrophy too expensive, HSE says

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may like
More>>

Drug for children with spinal muscular atrophy too expensive, HSE says

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may likeMore>>

You may like
More>>